Login to Your Account



Epizyme updates phase II data for tazemetostat

By Michael Fitzhugh
Staff Writer

Wednesday, June 14, 2017

Interim data from Epizyme Inc.’s ongoing phase II trial of EZH2 inhibitor tazemetostat boosted company shares Wednesday as investors embraced news that 92 percent of patients with relapsed or refractory follicular lymphoma and EZH2-activating mutations treated with the experimental therapy saw their tumors shrink.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription